Bihar's first merit list for the Four-Year Integrated B.Ed Programme 2025-28 is out. Admissions are scheduled from December 8 ...
Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback